Identification, characterization and suppression of side-products formed during the synthesis of high dose 68Ga-DOTA-TATE

Anon, 2009, Gallium (68Ga) edotreotide injection, Pharmeuropa, 21, 68 Anon, 2011, Gallium (68Ga) edotreotide injection, Pharmeuropa, 23, 310 Al-Nahhas, 2007, Gallium-68 PET—a new frontier in receptor cancer imaging, Anticancer Res., 27, 4087 Ambrosini, 2010, Ga-68-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors, J. Nucl. Med., 51, 669, 10.2967/jnumed.109.071712 Ambrosini, 2010, Ga-68-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours, Eur. J. Nucl. Med. Mol. Imaging, 37, 722, 10.1007/s00259-009-1349-9 Antunes, 2007, Are radiogallium-labeled DOTA-conjugated somatostatin analogs superior to those labeled with other radiometals?, Eur. J. Nucl. Med. Mol. Imaging, 34, 982, 10.1007/s00259-006-0317-x Bandoli, 2009, Mononuclear six-coordinated Ga(III) complexes—a comprehensive survey, Coord. Chem. Rev., 253, 56, 10.1016/j.ccr.2007.12.001 Conry, 2010, Comparison of Ga-68-DOTATATE and F-18-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma, Eur. J. Nucl. Med. Mol. Imaging, 37, 49, 10.1007/s00259-009-1204-z Decristoforo, 2007, A fully automated synthesis for the preparation of Ga-68-labeled peptides, Nucl. Med. Commun., 28, 870, 10.1097/MNM.0b013e3282f1753d Evans, 1966, Control of self-irradiation decomposition of tritium-labeled compounds at high specific activity, Nature, 209, 10.1038/209169a0 Evans, 1966, Stability of a radioactive drug-tetrasodium 2-methyl-1,4-naphthaquinol diphosphate labeled with tritium, Nature, 209, 10.1038/209196a0 Fawdry, 2007, Radiolysis of 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) and the role of reductant stabilisers, Appl. Radiat. Isot., 65, 1193, 10.1016/j.apradiso.2007.05.011 Garrison, 1987, Reaction-mechanisms in the radiolysis of peptides, polypeptides, and proteins, Chem. Rev., 87, 381, 10.1021/cr00078a006 Hofmann, 2001, Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68-DOTATOC: preliminary data, Eur. J. Nucl. Med., 28, 1751, 10.1007/s002590100639 Jacobson, 2009, Radiolysis of 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) and the role of ethanol and radioactive concentration, Appl. Radiat. Isot., 67, 990, 10.1016/j.apradiso.2009.01.005 Liu, 2001, Stabilization of (90)y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid, Bioconjugate Chem., 12, 554, 10.1021/bc000145v Maecke, 2005, Ga-68-labeled peptides in tumor imaging, J. Nucl. Med., 46, 172S Meyer, 2004, Ga-68-labeled DOTA-derivatised peptide ligands, Eur. J. Nucl. Med. Mol. Imaging, 31, 1097, 10.1007/s00259-004-1486-0 Papotti, 2002, Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors—a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis, Virchows Arch., 440, 461, 10.1007/s00428-002-0609-x Petrik, 2010, Impurity in (68)Ga-peptide preparation using processed generator eluate, J. Nucl. Med., 51, 495, 10.2967/jnumed.109.070953 Pettinato, 2008, Ga-68-DOTANOC—biodistribution and dosimetry in patients affected by neuroendocrine tumors, Eur. J. Nucl. Med. Mol. Imaging, 35, 72, 10.1007/s00259-007-0587-y Simat, 1998, Oxidation of free tryptophan and tryptophan residues in peptides and proteins, J. Agric. Food Chem., 46, 490, 10.1021/jf970818c Srirajaskanthan, 2010, The role of Ga-68-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on In-111-DTPA-octreotide scintigraphy, J. Nucl. Med., 51, 875, 10.2967/jnumed.109.066134 Virgolini, 2010, Procedure guidelines for PET/CT tumour imaging with Ga-68-DOTA-conjugated peptides: Ga-68-DOTA-TOC, Ga-68-DOTA-NOC, Ga-68-DOTA-TATE, Eur. J. Nucl. Med. Mol. Imaging, 37, 2004, 10.1007/s00259-010-1512-3 Wild, 2005, Ga-68-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5, Eur. J. Nucl. Med. Mol. Imaging, 32, 10.1007/s00259-004-1697-4